Loading
Life sciences · Journal article
Frontiers in Immunology · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lower anogenital tract malignancies comprise anatomically adjacent but biologically heterogeneous epithelial cancers of the cervix, vulva, vagina, anal canal and penis. This narrative and conceptual Review used a transparent literature search to examine how human papillomavirus (HPV) etiology intersects with tumor lineage, somatic alterations, antigen-presentation competence, immune-cell state and spatial organization. Evidence quality is heterogeneous: cervical cancer is supported by the largest genomic, single-cell, spatial and randomized-trial literature, whereas vaginal, vulvar and penile cancers remain constrained by small retrospective cohorts and cross-site extrapolation. HPV-associated tumors retain non-self E6/E7 antigens, but viral transcription does not ensure peptide presentation, dendritic-cell priming or epithelial access by functional T cells. HPV-independent tumors lack constitutive viral antigens yet may generate mutation- or differentiation-derived immunity and checkpoint-restrained myeloid–lymphoid niches. We therefore distinguish etiological status from functional immune phenotype and critically appraise three spatial architectures—an inflamed/epithelial-penetrating pattern, a stromally excluded pattern, and an immune-desert pattern—together with an immunosuppressive functional overlay that may occur in any architecture. Clinical evidence is graded separately from mechanistic inference: immune checkpoint blockade has established roles in defined cervical and anal cancer settings, whereas therapeutic vaccines, tumor-infiltrating lymphocytes, T-cell receptor-engineered therapies, myeloid or stromal sensitization and artificial-intelligence-guided selection remain investigational or context dependent. A three-tier biomarker framework is proposed, separating routine clinical assays from extended translational profiling and exploratory single-cell, spatial and artificial-intelligence methods. This framework is hypothesis-generating, not a validated treatment-selection algorithm; assay combinations, thresholds and incremental clinical utility require prospective, multicenter and site-stratified validation.